MSInsight

Founded in 2022, MSInsight operates from Boulogne-Billancourt, France, specializing in precision oncology. The company has completed one significant deal to date. The founder has not been disclosed, nor is there information about prior ventures.MSInsight specializes in precision oncology through its flagship product, MSIcare, which utilizes next-generation sequencing (NGS) technology to detect microsatellite instability (MSI) in both solid tumors and liquid biopsies. This diagnostic tool addresses a critical need for accurate identification of MSI, a significant biomarker linked to DNA repair system dysfunction, which plays a crucial role in determining patient eligibility for specific immunotherapies. Launched in 2022, MSIcare empowers healthcare providers by offering detailed genomic insights, enabling them to tailor treatment plans that enhance patient outcomes.The revenue model for MSInsight is based primarily on the provision of diagnostic services through its proprietary software, MSIcare. The company engages in B2B transactions with healthcare providers who integrate its diagnostic capabilities into their clinical workflows. Clients typically pay for MSI analysis services, which may include one-time fees for individual patient assessments or subscription models for ongoing access to the software and data analysis tools. These transactions facilitate comprehensive reporting on MSI status, aiding in the personalized treatment planning process for cancer patients. The company plans to expand its product line with enhancements to MSIcare and aims to penetrate new markets in Asia and North America by late 2025.

1. Seed

   Jan 7, 2025

   Amount

   $0.6M

   Investors

   Locked